Clinical Stage
This is a clinical-stage therapeutic, not a typical consumer RUO product. Information is provided for educational context about ongoing clinical research.
Evidence visual
Elamipretide evidence and risk matrix
advanced researcher fit
Evidence
Tier B
Risk
medium
Regulatory
investigational
WADA
none
FDA
unknown
Route
subcutaneous
Higher-confidence evidence profile, but regulatory and sourcing checks still matter.
Overview
Elamipretide (SS-31) is a mitochondria-targeting peptide that binds cardiolipin and stabilizes mitochondrial function, reducing ROS and improving energetics. Clinical trials span widely across IV infusion and other routes. Trial endpoints are measured over months in specific disease contexts. Not a typical consumer RUO peptide — positioned for clinical trial education/referrals.
Decision path
Where Elamipretide fits in the research path.
Use the evidence and risk profile first, then compare vendors and run the quiz before turning this compound into a protocol decision.
01
Read evidence
02
Check risk
03
Compare options
04
Build plan
Peptide research path
Decide whether Elamipretide belongs in your plan.
Use the quiz before choosing a compound, vendor, or PDF. It routes by goal, experience, budget, safety flags, and monitoring comfort.
Research Details
Binds cardiolipin, stabilizes mitochondrial function, reduces ROS and improves mitochondrial energetics.
subcutaneous, intravenous
Clinical trials: various IV infusion and other route protocols across disease programs.
Mitochondrial function improvement in disease contexts (clinical-stage).
Trial endpoints measured over months in disease-specific contexts.
Clinical trial context; not consumer self-administration.
Injection site reactions common in some trial summaries; long-term safety depends on indication.
Unknown in consumer context.
Cost at a glance
Typical cycle cost
€371.52
Estimated monthly
€371.52
Protocol style
Continuous / ongoing
Continuous
Estimate confidence
High confidence
Assumes roughly 60 mg–120 mg per cycle, using 1 tracked affiliated listing.
Clinical work uses daily ongoing administration, so pricing is modeled month by month.
Information provided for educational and research reference only. Not medical advice. Not for diagnosing, treating, curing, or preventing disease. Products referenced are labeled Research Use Only (RUO) by vendors; not for human or veterinary use.
Sources and review notes
- Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks - U.S. Food and Drug Administration - accessed 2026-05-15
Used for FDA compounding-risk context and peptide safety flags.
- The Prohibited List - World Anti-Doping Agency - accessed 2026-05-15
Used for athlete-facing WADA risk and peptide-class restrictions.
- Peptide therapeutics: current status and future directions - PubMed / Nature Reviews Drug Discovery - accessed 2026-05-15
Used for broad peptide-therapeutics background and evidence framing.
Personalized peptide routing
Find the right path for Elamipretide.
Take the quiz before choosing a compound, vendor, or PDF. We match your goal, experience, budget, and monitoring comfort to the next best step in the funnel.
- Goal-matched compound and protocol recommendations.
- Budget and sourcing filters before you leave the site.
- PDF unlocks shown after your personalized result.